
New FDA-Approved Nasal Spray Offers Hope for Treatment-Resistant Depression
The FDA has recently approved Spravato, a nasal spray designed to treat major depressive disorder (MDD) in adults who have not responded to at least two oral antidepressants. MDD is one of the most commonly diagnosed mental disorders globally, affecting hundreds of millions of people. Traditional antidepressants often take weeks to show results, and many patients do not achieve remission with a single medication. Studies indicate that only about 30% of individuals experience full symptom relief with one antidepressant, while 50% show no response at all.